Study of the effect of simultaneous treatment of breast cancer Cells with paclitaxel and sodium oxamate loaded in niosom

Abstract

1. Evan GI, Vousden KH. (2001). Proliferation, cell cycle and apoptosis in cancer. nature; 411(6835):342-48. 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians; 71(3):209-49. 3. Qaseem A, Lin JS, Mustafa RA, Horwitch CA, Wilt TJ, Physicians* CGCotACo. (2019). Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Annals of internal medicine; 170(8):547-60. 4. Hartwell LH, Kastan MB. (1994). Cell cycle control and cancer. Science; 266(5192):1821-28. 5. Graña X, Reddy EP. (1995). Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene; 11(2):211-20. 6. Nicolini A, Ferrari P, Duffy MJ, editors. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Seminars in cancer biology; 2018: Elsevier. 7. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. (2019). Immunotherapy and targeted therapy combinations in metastatic breast cancer. The lancet oncology; 20(3):e175-e86. 8. Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, et al. (2017). Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. Clinical chemistry; 63(2):532-41. 9. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical oncology; 26(8):1275-81. 10. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. (2006). Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer; 1766(1):63-78. 11. Jacobs TW, Byrne C, Colditz G, Connolly JL, Schnitt SJ. (1999). Radial scars in benign breast-biopsy specimens and the risk of breast cancer. New England Journal of Medicine; 340(6):430-36. 12. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. cell; 100(1):57-70. 13. Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science; 307(5706):58-62. 14. Jardé T, Perrier S, Vasson M-P, Caldefie-Chézet F. (2011). Molecular mechanisms of leptin and adiponectin in breast cancer. European journal of cancer; 47(1):33-43. 15. Stylianou S, Clarke RB, Brennan K. (2006). Aberrant activation of notch signaling in human breast cancer. Cancer research; 66(3):1517-25. 16. Schiff PB, Fant J, Horwitz SB. (1979). Promotion of microtubule assembly in vitro by taxol. Nature; 277(5698):665-67. 17. Haldar S, Chintapalli J, Croce CM. (1996). Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer research; 56(6):1253-55. 18. Zhao Z, Han F, Yang S, Wu J, Zhan W. (2015). Oxamate-mediated inhibition of lactate dehydrogenase induces protective autophagy in gastric cancer cells: Involvement of the Akt–mTOR signaling pathway. Cancer letters; 358(1):17-26. 19. Ranjbar-Navazi Z, Fathi M, Abdolahinia ED, Omidi Y, Davaran S. (2021). MUC-1 aptamer conjugated InP/ZnS quantum dots/nanohydrogel fluorescent composite for mitochondria-mediated apoptosis in MCF-7 cells. Materials Science and Engineering: C; 118:111469. 20. Ge X, Wei M, He S, Yuan W-E. (2019). Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics; 11(2):55. 21. Kaur D, Kumar S. (2018). Niosomes: present scenario and future aspects. Journal of drug delivery and therapeutics; 8(5):35-43. 22. Azamjah N, Soltan-Zadeh Y, Zayeri F. (2019). Global trend of breast cancer mortality rate: a 25-year study. Asian Pacific journal of cancer prevention: APJCP; 20(7):2015. 23. Ly D, Forman D, Ferlay J, Brinton LA, Cook MB. (2013). An international comparison of male and female breast cancer incidence rates. International journal of cancer; 132(8):1918-26. 24. Ren YF, Zhang TH, Zhong S, Zhao YT, Lv YN. (2018). miR‑144 suppresses proliferation and induces apoptosis of osteosarcoma cells via direct regulation of mTOR expression. Oncology letters; 15(1):1163-69. 25. Momenimovahed Z, Salehiniya H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy; 11:151. 26. Youlden DR, Cramb SM, Yip CH, Baade PD. (2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer biology & medicine; 11(2):101. 27. Brook A, Homaie F, Tavakkol Afshari J, Ganjali R, Afzalaghaee M. (2011). 1. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007 13 (4): 383-91. Armaghane danesh; 15(4):316-24. 28. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, et al. (2009). Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC cancer; 9(1):1-15. 29. Al-Thoubaity FK. (2020). Molecular classification of breast cancer: A retrospective cohort study. Annals of medicine and surgery; 49:44-48. 30. Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. (2015). Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. The journal of breast health; 11(2):59. 31. Toft DJ, Cryns VL. (2011). Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Molecular Endocrinology; 25(2):199-211. 32. Kondov B, Milenkovikj Z, Kondov G, Petrushevska G, Basheska N, Bogdanovska-Todorovska M, et al. (2018). Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients. Open access Macedonian journal of medical sciences; 6(6):961. 33. Group EBCTC. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. The lancet; 378(9793):771-84. 34. Joshi H, Press MF. Molecular oncology of breast cancer. The Breast: Elsevier; 2018. p. 282-307. e5. 35. Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine; 376(22):2147-59. 36. Waks AG, Winer EP. (2019). Breast cancer treatment: a review. Jama; 321(3):288-300. 37. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. (2012). Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer treatment reviews; 38(7):890-903. 38. Park S-J, Wu C-H, Gordon JD, Zhong X, Emami A, Safa AR. (2004). Taxol induces caspase-10-dependent apoptosis. Journal of Biological Chemistry; 279(49):51057-67. 39. Prajapati V, Kale RK, Singh RP. (2015). Silibinin combination with arsenic strongly inhibits survival and invasiveness of human prostate carcinoma cells. Nutrition and cancer; 67(4):647-58. 40. Muramatsu H, Sumitomo M, Morinaga S, Kajikawa K, Kobayashi I, Nishikawa G, et al. (2019). Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells. Oncology reports; 42(1):224-30. 41. Miskimins WK, Ahn HJ, Kim JY, Ryu S, Jung Y-S, Choi JY. (2014). Synergistic anti-cancer effect of phenformin and oxamate. PloS one; 9(1):e85576. 42. Makvandi P, Caccavale C, Della Sala F, Zeppetelli S, Veneziano R, Borzacchiello A. (2020). Natural formulations provide antioxidant complement to hyaluronic acid-based topical applications used in wound healing. Polymers; 12(8):1847. 43. Li Y, Le TMD, Bui QN, Yang HY, Lee DS. (2019). Tumor acidity and CD44 dual targeting hyaluronic acid-coated gold nanorods for combined chemo-and photothermal cancer therapy. Carbohydrate polymers; 226:115281. 44. Cai W, Gao T, Hong H, Sun J. (2008). Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology, science and applications; 1:17. 45. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. (2007). Characterization of nanoparticles for therapeutics. 46. Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, et al. (2014). Niosomes from 80s to present: the state of the art. Advances in colloid and interface science; 205:187-206. 47. Yu H-P, Liu F-C, Umoro A, Lin Z-C, Elzoghby AO, Hwang T-L, et al. (2020). Oleic acid-based nanosystems for mitigating acute respiratory distress syndrome in mice through neutrophil suppression: how the particulate size affects therapeutic efficiency. Journal of Nanobiotechnology; 18(1):1-16. 48. Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A. (2018). Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier. Advances in pharmacological sciences; 2018. 49. Dey NS, Rao MB. (2011). Quantum dot: Novel carrier for drug delivery. Int J Res Pharm Biomed Sci; 2(2):448-58. 50. Alivisatos AP. (1996). Semiconductor clusters, nanocrystals, and quantum dots. science; 271(5251):933-37. 51. Cui L, Li C-c, Tang B, Zhang C-y. (2018). Advances in the integration of quantum dots with various nanomaterials for biomedical and environmental applications. Analyst; 143(11):2469-78. 52. Porsiel JC, Temel B, Schirmacher A, Buhr E, Garnweitner G. (2019). Dimensional characterization of cadmium selenide nanocrystals via indirect Fourier transform evaluation of small-angle X-ray scattering data. Nano Research; 12(11):2849-57. 53. Ag Seleci D, Maurer V, Barlas FB, Porsiel JC, Temel B, Ceylan E, et al. (2021). Transferrin-decorated niosomes with integrated InP/ZnS quantum dots and magnetic iron oxide nanoparticles: dual targeting and imaging of glioma. International journal of molecular sciences; 22(9):4556. 54. Nowroozi F, Dadashzadeh S, Soleimanjahi H, Haeri A, Shahhosseini S, Javidi J, et al. (2018). Theranostic niosomes for direct intratumoral injection: marked enhancement in tumor retention and anticancer efficacy. Nanomedicine; 13(17):2201-19. 55. Gligorov J, Lotz JP. (2004). Preclinical pharmacology of the taxanes: implications of the differences. The oncologist; 9(S2):3-8. 56. Weaver BA. (2014). How Taxol/paclitaxel kills cancer cells. Molecular biology of the cell; 25(18):2677-81. 57. Markman M, Mekhail TM. (2002). Paclitaxel in cancer therapy. Expert opinion on pharmacotherapy; 3(6):755-66. 58. Moghassemi S, Hadjizadeh A. (2014). Nano-niosomes as nanoscale drug delivery systems: an illustrated review. Journal of controlled release; 185:22-36. 59. Fathi M, Zangabad PS, Aghanejad A, Barar J, Erfan-Niya H, Omidi Y. (2017). Folate-conjugated thermosensitive O-maleoyl modified chitosan micellar nanoparticles for targeted delivery of erlotinib. Carbohydrate polymers; 172:130-41. 60. Barar J, Omidi Y. (2014). Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. BioImpacts: BI; 4(1):3. 61. Hiscox S, Baruah B, Smith C, Bellerby R, Goddard L, Jordan N, et al. (2012). Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC cancer; 12(1):1-14. 62. Bhattacharya DS, Svechkarev D, Souchek J, Hill TK, Taylor M, Natarajan A, et al. (2017). Impact of structurally modifying hyaluronic acid on CD44 interaction. Journal of Materials Chemistry B; 5(41):8183-92. 63. Khan MI, Madni A, Ahmad S, Khan A, Rehmanand M, Mahmood MA. (2015). ATR-FTIR Based Pre and Post Formulation Compatibility Studies for the Design of Niosomal Drug Delivery System Containing Nonionic Amphiphiles and Chondroprotective Drug. Journal of the Chemical Society of Pakistan; 37(3). 64. Mehta S, Jindal N. (2013). Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs. Colloids and Surfaces B: Biointerfaces; 101:434-41. 65. Samed N, Sharma V, Sundaramurthy A. (2018). Hydrogen bonded niosomes for encapsulation and release of hydrophilic and hydrophobic anti-diabetic drugs: an efficient system for oral anti-diabetic formulation. Applied Surface Science; 449:567-73. 66. Al-Sibani M, Al-Harrasi A, Neubert R. (2018). Characterization of linear and chemically cross-linked hyaluronic acid using various analytical techniques including FTIR, ESI-MS, H1 NMR, and SEM. J Biochem Anal Stud; 3:1-8. 67. Lee ES, Na K, Bae YH. (2005). Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. Journal of controlled release; 103(2):405-18.

Abstract : Nowadays, most studies on breast cancer focused on the application of nanoparticles (NPs) in chemotherapy. Niosomes (NIOs) as nanovesicles have advantages such as carrying both hydrophobic and hydrophilic drugs, nontoxicity, low cost, and biodegradability making them distinct from other nanocarriers. Besides, NIOs in combination with quantum dots (QDs) as bioimaging agents and hyaluronic acid (HA) as a targeting agent containing paclitaxel (PTX) along with other therapeutic agents such as sodium oxamate (SO) can be considered a great candidate for effective cancer therapy.

Methods: NIO/QDs/HA/PTX/SO NPs were synthesized by thin-film hydration methods and their characteristics such as size and surface morphology were determined by DLS, TEM, respectively. More over, the structure of the NPs was assessed by FT-IR. Cell viability was examined by MTT in 24, 48, 72 hours. Also, for cell apoptosis, the treated cells were checked in during 72 hours, to study the effects of sodium hexamate on the pathways of ATP production, as well as the production of reactive oxygen species in mitochondria, a mitochondrial kit was used, and the cell cycle was examined by FACS Calibur flow cytometry Results: It was demonstrated by PTX-loaded NIO/QDs/HA NPs increased mortality of cells in comparison to free-drug. The investigation of niosome complex with a concentration of 5 ppm by MTT test in 72 hours showed IC50 that other tests, apoptosis, cell cycle and mitochondrial pathways were also investigated with a concentration of 5 ppm. Conclution: The findings have shown that the simultaneous encapsulation of PTX and SO in NIO/QDs/HA NPs enhance the treatment of PTX on cancer cells and can be introduced as an efficient treatment for breast cancer Keywords: Niosomes, Quantum dots, Hyaluronic acid, Paclitaxel, Sodium oxamate, Breast cancer,Drug delivery systems